V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160012282 | 160005877 | 1.73 | 86 | Neo-adjuvant (N) | 2018-10-21 | 2018-10-21 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100069395 |
| 160012284 | 160005878 | 1.65 | 84.6 | Neo-adjuvant (N) | 2017-08-26 | 2017-08-27 | Rituximab | 02 | N | CISPLATIN + PACLITAXEL | 101538934 |
| 160012285 | 160005879 | 1.78 | 89.6 | Neo-adjuvant (N) | 2019-07-14 | 2019-08-01 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101011587 |
| 160012286 | 160005880 | 1.56 | 89.6 | Neo-adjuvant (N) | 2016-01-20 | 2016-02-03 | CARBOPLATIN | 02 | N | CARBOPLATIN | 101558579 |
| 160012288 | 160005881 | 1.8 | 71.8 | Neo-adjuvant (N) | 2017-12-10 | 2017-12-11 | Cisplatin + Pemetrexed | 02 | Y | CISPLATIN + PEMETREXED | 100085696 |
| 160012289 | 160005882 | 1.8 | 70 | Palliative (P) | 2018-02-10 | 2018-02-24 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100574817 |
| 160012291 | 160005883 | 1.69 | 81.8 | Neo-adjuvant (N) | 2019-09-23 | 2019-09-25 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100015891 |
| 160012292 | 160005884 | 1.69 | 55.2 | Curative (C) | 2019-08-03 | 2019-08-17 | Trial Unspecified | 02 | N | TRIAL UNSPECIFIED | 101827231 |
| 160012294 | 160005885 | 0 | 12.5 | Palliative (P) | 2018-12-12 | 2018-12-29 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100579814 |
| 160012296 | 160005886 | 1.65 | 65 | Palliative (P) | 2016-04-15 | 2016-04-22 | NB HRNBL-1 COJEC Ind COURSE B | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100076451 |
| 160012298 | 160005887 | 1.69 | 55.1 | Palliative (P) | 2017-12-16 | 2017-12-16 | Cisplatin + Pemetrexed | 02 | Y | CISPLATIN + PEMETREXED | 100124672 |
| 160012299 | 160005888 | 1.78 | 81.6 | Palliative (P) | null | 2016-04-18 | Trial Unspecified | 02 | N | TRIAL UNSPECIFIED | 100896238 |
| 160012300 | 160005889 | 1.43 | 63.9 | Disease modification (D) | 2020-01-03 | 2020-01-05 | Bevacizumab+Carbo+Pacliaxel | 02 | N | IMATINIB | 100706098 |
| 160012301 | 160005890 | 1.7 | 84.35 | Curative (C) | 2017-05-13 | 2017-05-25 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101789839 |
| 160012303 | 160005891 | 1.59 | 52.45 | Palliative (P) | 2015-02-25 | 2015-03-19 | null | 02 | N | CARBOPLATIN | 100267941 |
| 160012304 | 160005892 | 1.89 | 67.1 | Palliative (P) | 2019-06-29 | 2019-07-09 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100231334 |
| 160012307 | 160005893 | 1.78 | 70 | Palliative (P) | 2016-06-28 | 2016-06-28 | Doxorubicin + Ifosfamide | N | N | PEMETREXED | 101775479 |
| 160012308 | 160005894 | null | 58.5 | Palliative (P) | 2016-05-02 | 2016-05-02 | null | N | null | LIPOSOMAL DOXORUBICIN | 100415013 |
| 160012309 | 160005895 | 1.84 | 86 | Palliative (P) | 2016-10-30 | 2016-11-21 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100095428 |
| 160012310 | 160005896 | 1.88 | 96.4 | Palliative (P) | 2019-05-18 | 2019-05-18 | Cisplatin + Pemetrexed | null | null | CISPLATIN + PEMETREXED | 100331090 |
| 160012311 | 160005897 | 1.74 | 70 | Palliative (P) | 2018-04-21 | 2018-05-03 | Trial Unspecified | N | null | DOXORUBICIN | 100063852 |
| 160012312 | 160005898 | 1.54 | 61.2 | Neo-adjuvant (N) | 2020-01-15 | 2020-01-29 | NB HRNBL-1 COJEC Ind COURSE A | 02 | N | NOT MATCHED | 100645817 |
| 160012313 | 160005899 | 1.79 | 60 | Neo-adjuvant (N) | 2018-07-20 | 2018-08-19 | Doxorubicin + Ifosfamide | 02 | N | TRIAL UNSPECIFIED | 101264526 |
| 160012316 | 160005900 | 1.72 | 66.7 | Palliative (P) | 2017-11-21 | 2017-11-28 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101268701 |
| 160012320 | 160005901 | 1.56 | 73 | Curative (C) | 2018-12-16 | 2019-01-06 | Carboplatin AUC 2 - 5 | N | N | CARBOPLATIN | 101026149 |
| 160012321 | 160005902 | 1.73 | 73.8 | Neo-adjuvant (N) | 2016-02-07 | 2016-02-14 | Liposomal Doxorubicin (Caelyx) | 02 | N | DOXORUBICIN | 100713731 |
| 160012324 | 160005903 | 1.6 | 63.5 | Palliative (P) | 2016-05-15 | 2016-05-15 | Doxorubicin + Ifosfamide | 02 | N | TRABECTEDIN | 101505746 |
| 160012325 | 160005904 | null | 71 | Curative (C) | 2019-03-03 | 2019-03-15 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100859172 |
| 160012331 | 160005907 | 1.75 | 65 | Neo-adjuvant (N) | 2017-06-10 | 2017-06-24 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100754499 |
| 160012333 | 160005909 | 1.64 | 88.6 | Palliative (P) | 2019-11-18 | 2019-11-26 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100798749 |
| 160012334 | 160005910 | 1.75 | 71.1 | Palliative (P) | 2018-06-07 | 2018-06-07 | Cisplatin + Docetaxel +Fluorouracil | 02 | N | NIVOLUMAB | 100059008 |
| 160012335 | 160005911 | 1.62 | 65.2 | 03 | null | 2021-03-30 | STS Rhabdomyosarco RMS 2005 IVADoVV | 02 | N | NOT MATCHED | 101806115 |
| 160012337 | 160005912 | null | null | Palliative (P) | 2018-04-29 | 2018-05-29 | Trial Unspecified | 01 | N | TRIAL UNSPECIFIED | 101647755 |
| 160012340 | 160005913 | 1.7 | 69.9 | Palliative (P) | 2019-09-07 | 2019-09-08 | EW EuroEwing 2012 Arm A VAC | 99 | N | IVADO | 100886950 |
| 160012342 | 160005914 | 1.67 | 44.7 | Palliative (P) | 2017-12-11 | 2017-12-15 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101315252 |
| 160012343 | 160005915 | 1.72 | 81 | Palliative (P) | 2018-11-26 | 2018-11-26 | NB HRNBL-1 MOD N7 CAV | N | N | DOXORUBICIN + IFOSFAMIDE | 101591497 |
| 160012344 | 160005916 | 1.6 | 70.2 | Palliative (P) | 2016-03-27 | 2016-04-07 | ETOP 13-18 BEAT-meso Trial | null | N | BEVACIZUMAB + CARBO + PACLITAXEL | 101060185 |
| 160012345 | 160005917 | null | 30 | Palliative (P) | null | 2019-02-28 | Doxorubicin + Ifosfamide | N | N | IMATINIB | 100930354 |
| 160012346 | 160005918 | 1.8 | 117 | Palliative (P) | 2020-01-31 | 2020-02-08 | Cisplatin + Pemetrexed | 2 | null | CISPLATIN + PEMETREXED | 101019332 |
| 160012347 | 160005919 | 1.7 | 82.4 | Palliative (P) | 2017-12-20 | 2017-12-20 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | null | LIPOSOMAL DOXORUBICIN | 101116320 |
| 160012348 | 160005920 | 1.72 | 64.4 | Palliative (P) | 2017-06-18 | 2017-07-01 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101195581 |
| 160012350 | 160005921 | 1.72 | 95 | Curative (C) | 2017-12-05 | 2017-12-08 | Liposomal Doxorubicin (Caelyx) | 01 | N | DACTINOMYCIN + VINCRISTINE | 101838558 |
| 160012353 | 160005922 | 1.56 | 59 | Neo-adjuvant (N) | null | 2021-04-11 | STS Rhabdomyosarco RMS 2005 IVADoVV | null | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 100272033 |
| 160012354 | 160005923 | 1.73 | 72.6 | Palliative (P) | 2021-01-05 | 2021-01-23 | STS Rhabdo RMS 2005 | 02 | N | DOXORUBICIN | 100478505 |
| 160012356 | 160005924 | 1.83 | 68 | Neo-adjuvant (N) | 2017-06-03 | 2017-06-06 | Cisplatin + Pemetrexed | 2 | N | CISPLATIN + PEMETREXED | 100699868 |
| 160012357 | 160005925 | 1.6 | 64.2 | Palliative (P) | 2017-03-03 | 2017-03-24 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100872232 |
| 160012359 | 160005926 | 1.8 | 54.8 | Curative (C) | 2018-04-08 | 2018-04-08 | Carboplatin + Paclitaxel (3 weekly) | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100465135 |
| 160012360 | 160005927 | 1.82 | 100.1 | Neo-adjuvant (N) | 2018-02-24 | 2018-03-03 | VIDE | 02 | null | DOXORUBICIN | 100569446 |
| 160012361 | 160005928 | 1.82 | 64.7 | null | null | 2017-05-15 | NB Low/Interm risk guidelines Carbo/Etop | 02 | null | DOXORUBICIN | 100464990 |
| 160012364 | 160005929 | 1.76 | 69.9 | Curative (C) | 2020-07-17 | 2020-07-31 | Cisplatin + Pemetrexed | 2 | N | CISPLATIN + PEMETREXED | 100129638 |